

Supplementary Table 2. The risk of NAFLD according to myosteatosi indices in the total population

Variable	Q1	Q2	Q3	Q4	P for trend
SMA/BMI					
Prevalence	1,541/3,363 (45.8)	1,279/3,363 (38.0)	1,032/3,363 (30.7)	715/3,362 (21.3)	
Unadjusted	3.13 (2.81–3.48)	2.27 (2.04–2.53)	1.64 (1.47–1.83)	1 (ref)	<0.001
Multivariable	2.43 (2.13–2.76)	1.90 (1.67–2.15)	1.44 (1.27–1.64)	1 (ref)	<0.001
NAMA/BMI					
Prevalence	1,583/3,362 (47.1)	1,294/3,364 (38.5)	1,014/3,363 (30.2)	676/3,362 (20.1)	
Unadjusted	3.54 (3.17–3.94)	2.48 (2.23–2.77)	1.72 (1.53–1.92)	1 (ref)	<0.001
Multivariable	2.76 (2.41–3.16)	1.97 (1.74–2.25)	1.46 (1.28–1.66)	1 (ref)	<0.001
NAMA/TAMA					
Prevalence	1,506/3,363 (44.8)	1,252/3,363 (37.2)	1,069/3,364 (31.8)	741/3,362 (22.0)	
Unadjusted	2.87 (2.58–3.19)	2.10 (1.88–2.34)	1.65 (1.48–1.84)	1 (ref)	<0.001
Multivariable	2.12 (1.86–2.42)	1.68 (1.48–1.91)	1.42 (1.25–1.61)	1 (ref)	<0.001
LAMA/BMI					
Prevalence	833/3,361 (24.8)	1,102/3,364 (32.8)	1,253/3,363 (37.3)	1,379/3,363 (41.0)	
Unadjusted	0.47 (0.43–0.53)	0.70 (0.64–0.77)	0.85 (0.78–0.94)	1 (ref)	<0.001
Multivariable	0.63 (0.55–0.71)	0.81 (0.72–0.91)	0.96 (0.86–1.07)	1 (ref)	<0.001

Values are presented as number (%) or odds ratio (95% confidence interval). Multivariable analysis adjusted for age, smoking status, alcohol consumption, regular exercise, hypertension, diabetes, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and alanine aminotransferase.

NAFLD, nonalcoholic fatty liver disease; SMA, skeletal muscle area; BMI, body mass index; NAMA, normal attenuation muscle area; TAMA, total abdominal muscle area; LAMA, low attenuation muscle area.